Blood News and Research

RSS

Clinical performance study reveals the accuracy and precision of TRUE2go system

Home Diagnostics, Inc., a leading developer, manufacturer, and marketer of blood glucose monitoring systems, today announced the results of a TRUE2go™ clinical performance study published in the October 2009 issue of the journal Diabetes Technology & Therapeutics. The study, “Clinical Performance of the TRUE2go Blood Glucose System – A Novel Integrated System for Meter and Strips,” demonstrated the accuracy and precision of the TRUE2go system and found that it was both easy and convenient to use by patients.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

VeriChip Corporation announced today that it has entered into a strategic partnership with the Diabetes Research Institute ("DRI") to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.

22 Oct 2009

Study results of PTH1-34 oral parathyroid hormone presented

Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere’s proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

New findings from ADVANCE clinical trial presented

New analyses of the largest-ever clinical trial of patients with type 2 diabetes show that the combination of blood pressure lowering treatment and intensive glucose (blood sugar) control improved patients' vascular condition and resulted in a significant 18 percent reduction in the risk of death from all causes.

22 Oct 2009

Blood test to identify MCI patients at risk of Alzheimer's disease

Elderly people exhibiting memory disturbances that do not affect their normal, daily life suffer from a condition called "mild cognitive impairment" (MCI). Some MCI patients go on to develop Alzheimer's disease within a few years, whereas other cases remain stable, exhibiting only benign senile forgetfulness. It is crucial to develop simple, blood-based tests enabling early identification of these patients that will progress in order to begin therapy as soon as possible, potentially delaying the onset of dementia.

22 Oct 2009

Media outlets examine how AIDS vaccine trial results will shape future studies

As the AIDS vaccine conference continues in Paris this week, Reuters examines how recent trials are helping researchers better understand ways to develop a vaccine that offers people protection from HIV.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

Gates Foundation awards Vanderbilt University $100,000 for developing a malaria diagnostic test

Vanderbilt University announced Oct. 21 that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Associate Professor of Chemistry David Wright and Professor of Biomedical Engineering Rick Haselton, titled "Coffee Ring Stain Diagnostics for Malaria."

22 Oct 2009

Crux Biomedical receives U.S. patent for its novel vena cava filter

Crux Biomedical Inc. announced today that it was awarded a U.S. patent, (US 7,582,100 B2), for its novel vena cava filter.

22 Oct 2009

AAAS and partners to launch online social-networking sites for scientists

To help scientists and science trainees who hope to translate laboratory research into clinical medicine and to help minority scientists navigate their career paths, AAAS, Science Careers, and Science are launching a pair of online social-networking sites.

22 Oct 2009

New diabetes algorithm released by AACE for the management of type 2 diabetes

A new, first-of-its-kind diabetes algorithm created to help achieve glycemic (blood sugar) control in type 2 patients was published online today in the September/October edition of Endocrine Practice.

22 Oct 2009

NIH awards $8 million to The Medical College of Wisconsin for heart research

The Medical College of Wisconsin has been awarded a five-year, $8 million, multi-investigator Program Project Grant (PPG) from the National Institutes of Health to understand how human pluripotent stem cells, defined as cells which if left to their own designs can develop into any of the more than 200 cell types in the human body, can be channeled to exclusively become heart muscle cells.

22 Oct 2009

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

The Century Council provides $100,000 research grant to EMF

As part of a multi-faceted initiative geared to significantly reduce college binge drinking and coinciding with National Collegiate Alcohol Awareness Week, The Century Council, a not-for-profit organization funded by distillers dedicated to fighting drunk driving and underage drinking, has provided a $100,000 research grant to the Emergency Medicine Foundation (EMF) to learn more about the role of emergency services with regard to college binge drinking.

21 Oct 2009

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

21 Oct 2009

Maternal smoking may increase the level of distress of newborns, says study

A new research study being published in the October 15th issue of Biological Psychiatry suggests that maternal smoking may increase the level of distress of newborns.

21 Oct 2009

Study reveals a dramatic increase in TTB cases

Babesiosis is a potentially dangerous parasitic disease transmitted by ticks and is common in the Northeast and the upper Midwest. Babesia lives inside of red blood cells, meaning it can also be transmitted through a blood transfusion from an infected but otherwise asymptomatic blood donor.

21 Oct 2009